Annual report pursuant to Section 13 and 15(d)

Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)

v3.23.2
Description of Business and Summary of Significant Accounting Policies - Additional Information (Details)
$ in Thousands
1 Months Ended 3 Months Ended 12 Months Ended
Nov. 29, 2022
shares
Sep. 01, 2022
USD ($)
Dec. 31, 2021
USD ($)
Mar. 31, 2023
USD ($)
Sep. 30, 2022
USD ($)
shares
Jun. 30, 2023
USD ($)
item
shares
Jun. 30, 2022
USD ($)
item
shares
Jun. 30, 2021
USD ($)
item
Proceeds from Divestiture of Interest in Consolidated Subsidiaries           $ 17,824    
Revenue from Contract with Customer, Excluding Assessed Tax           1,136,702 $ 1,105,599 $ 931,032
Gain on sale of Eminence           11,682    
Gain (loss) on equity method investment           (1,143)    
Goodwill, Impairment Loss             $ 8,275  
Payments to Acquire Investments, Total           $ 232,000    
Common stock, shares authorized (in shares) | shares 400,000,000       100,000,000 400,000,000 400,000,000  
Declared stock split 4              
Additional shares | shares 3              
Number of reporting units | item           5 5 5
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)             $ 8,563  
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]             Selling, general and administrative  
Goodwill, Impairment Loss             $ 8,275  
Eminence Biotechnology                
Proceeds from Divestiture of Interest in Consolidated Subsidiaries   $ 17,800            
Goodwill, Impairment Loss             8,300  
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)             8,600  
Goodwill, Impairment Loss             8,300  
Protein Sciences                
Goodwill, Impairment Loss             8,275  
Pre-tax restructuring charges           $ 1,700    
Goodwill, Impairment Loss             8,275  
Protein Sciences | Eminence Biotechnology                
Revenue from Contract with Customer, Excluding Assessed Tax         $ 2,000   4,600  
Diagnostics and Genomics                
Pre-tax restructuring charges             1,400  
Wilson Wolf Corporation [Member]                
Investment percentage       19.90%        
Gain (loss) on equity method investment           (1,100)    
Investment amount           $ 256,000    
Payments to Acquire Investments, Total     $ 25,000 $ 232,000        
Forward Contract, Milestone, Multiple for Total Expected Payments           4.4    
Wilson Wolf Corporation [Member] | First Part of Forward Contract [Member]                
Forward Contract, Milestone, Annual Revenue Required           $ 92,000    
Forward Contract, Milestone, Annual EBITDA           55,000    
Wilson Wolf Corporation [Member] | Second Part of Forward Contract [Member]                
Forward Contract, Milestone, Annual Revenue Required           226,000    
Forward Contract, Milestone, Annual EBITDA           136,000    
Forward Contract, Additional Investment           1,000,000    
QT Holdings Corporation | Protein Sciences                
Pre-tax restructuring charges           $ 2,200    
Eminence Biotechnology                
Inventory Write-down             900  
Asset Impairment Charges, Total             $ 900  
Eminence Biotechnology | Nonoperating Income (Expense) [Member]                
Gain on sale of Eminence         $ 11,700